Press "Enter" to skip to content

Analysis of Diabetes Care Drugs Market 2019-2024: Industry Trends, Share, Size, Price, Revenue, Business Strategy, Production Technology Forecast to 2024

Diabetes

The “Diabetes Care Drugs Market” research report 2019-2024 delivers comprehensive information and valuable insights about the Diabetes Care Drugs industry. The information available in the Diabetes Care Drugs market report is not only based on the facts but also on the case studies, which analysts have included to convey appropriate information to the clients in a well-versed manner. Diabetes Care Drugs market report includes valuable information to assist new entrants, as well as established players, to understand the prevailing trends in the market.

Some Companies Are Covered in the Diabetes Care Drugs Market:

  • Novo Nordisk
  • Sanofi
  • Eli Lilly
  • Takeda
  • Pfizer
  • Janssen Pharmaceuticals
  • Astellas
  • Boehringer Ingelheim
  • Merck and Co.
  • AstraZeneca
  • Bristol Myers Squibb
  • Novartis

    Get a Sample Copy of the Report – https://www.industryresearch.co/enquiry/request-sample/14244205

    Market Overview:

  • – The market size, in 2017, for the global diabetes drugs market was registered to be USD 67.5 billion, and the market is expected to record a CAGR of 5.65% during the forecast period, 2019-2024.
  • – North America dominates the market, followed by Asia-Pacific.
  • – Diabetes or diabetes mellitus, describes a group of metabolic diseases in which the person has high blood glucose (blood sugar), either because insulin production is inadequate or one does not produce insulin (known as Type 1 diabetes), or because the body’s cells do not respond properly to insulin (known as Type 2 diabetes), or both.
  • – Approximately 10% of all diabetes cases are Type 1, and approximately 90% of all cases of diabetes worldwide are of Type 2.

    Scope of the Report:

  • The global diabetes care drugs market is segmented by category (insulin, oral anti-diabetic drugs, non-insulin injectable drugs, and combination drugs), by segment (basal or long-acting, bolus or fast-acting, traditional human insulin drugs, insulin biosimilars, GLP-1 receptor agonists, alpha-glucosidase inhibitors, DPP-4 inhibitors, and SGLT-2 inhibitors) and by geography.

    Reasons for Buying Diabetes Care Drugs Market Report:

    • This report provides pin-point analysis for changing competitive dynamics
    • It provides a forward looking perspective on different factors driving or restraining market growth
    • It provides a five-year forecast assessed on the basis of how the market is predicted to grow
    • It helps in understanding the key product segments and their future
    • It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
    • It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

    For More Information or Query or Customization Before Buying, Visit at – https://www.industryresearch.co/enquiry/pre-order-enquiry/14244205

    Key Market Trends:

    Rising Prevalence of Diabetes

    – As per a WHO report, the global prevalence of diabetes among adults of over 18 years had accelerated from about 4.7%, in 1980, to over 8.5%, in 2014.
    – Diabetes prevalence has been rising rapidly in the middle- and low-income countries. In 2015, about 1.6 million deaths were directly associated with diabetes, which was around 2.2 million in 2012.
    – Almost half of all deaths attributable to high blood glucose occur before the age of 70 years. WHO projects that diabetes is likely to be the seventh leading cause of death by 2030.
    – Statistics prove that one in ten individuals in the world has diabetes and a rise in this trend is expected to take the situation to one in three by 2050 (according to the Center for Disease Control and Prevention).
    – The growing prevalence of diabetes is the major driver for the global diabetes care drugs market. Additionally, rising awareness regarding diabetes care, growing prevalence of obesity, and technological advancements are further driving the market.

    The United States Leads the Diabetes Drugs Market in North America

    – In 2017, the US diabetes drugs market held the largest market share in North America, due to the presence of a high-quality healthcare system and increasing prevalence of diabetes in the region.
    – In the Asia-Pacific region, China and India have been identified as potential emerging markets, due to the rising diabetic population in this region.

    Diabetes Care Drugs Market Report Provides Comprehensive Analysis of:

    • Functional market industry outline
    • Up and downstream industry examination
    • Channels and propositions believability
    • Market challenge by key players
    • Enhancement suggestions examination

    Purchase this Report (Price 6000 USD for single user license) – https://www.industryresearch.co/purchase/14244205

    Report Highlights:

    • Market Dynamics – Drivers, Restraints, and Opportunities
    • Market Segmentation – Types, Applications, Regions, and Technology
    • Market Trends
    • Competitive Landscape
    • SWOT Analysis and Porter’s Five Forces Analysis

    Detailed TOC of Diabetes Care Drugs Market Report 2019-2024:

    1 INTRODUCTION
    1.1 Study Deliverables
    1.2 Study Assumptions
    1.3 Scope of the Study

    2 RESEARCH METHODOLOGY

    3 EXECUTIVE SUMMARY

    4 MARKET DYNAMICS
    4.1 Market Overview
    4.2 Drivers
    4.3 Restraints
    4.4 Porter’s Five Forces Analysis
    4.4.1 Bargaining Power of Suppliers
    4.4.2 Bargaining Power of Consumers
    4.4.3 Threat of New Entrants
    4.4.4 Threat of Substitute Products and Services
    4.4.5 Intensity of Competitive Rivalry

    5 MARKET SEGMENTATION
    5.1 By Drug
    5.1.1 Oral Anti-diabetic drugs (Value and Volume 2012-2024)
    5.1.1.1 Biguanides
    5.1.1.1.1 Metformin
    5.1.1.2 Alpha-Glucosidase Inhibitors
    5.1.1.3 Dopamine -D2 Receptor Agonist
    5.1.1.3.1 Cycloset (Bromocriptin)
    5.1.1.4 Sodium-glucose Cotransport -2 (SGLT-2) Inhibitors
    5.1.1.4.1 Invokana (Canagliflozin)
    5.1.1.4.2 Jardiance (Empagliflozin)
    5.1.1.4.3 Farxiga/Forxiga (Dapagliflozin)
    5.1.1.4.4 Suglat (Ipragliflozin)
    5.1.1.5 Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
    5.1.1.5.1 Januvia (Sitagliptin)
    5.1.1.5.2 Onglyza (Saxagliptin)
    5.1.1.5.3 Tradjenta (Linagliptin)
    5.1.1.5.4 Vipidia/Nesina (Alogliptin)
    5.1.1.5.5 Galvus (Vildagliptin)
    5.1.1.6 Sulfonylureas
    5.1.1.7 Meglitinides
    5.1.2 Insulins (Value and Volume 2012-2024)
    5.1.2.1 Basal or Long-acting Insulin
    5.1.2.1.1 Lantus (Insulin Glargine)
    5.1.2.1.2 Levemir (Insulin Detemir)
    5.1.2.1.3 Toujeo (Insulin Glargine)
    5.1.2.1.4 Tresiba (Insulin Degludec)
    5.1.2.1.5 Basaglar (Insulin Glargine)
    5.1.2.2 Bolus or Fast-acting Insulin
    5.1.2.2.1 NovoRapid/Novolog (Insulin Aspart)
    5.1.2.2.2 Humalog (Insulin Lispro)
    5.1.2.2.3 Apidra (Insulin Glulisine)
    5.1.2.3 Traditional Human Insulin
    5.1.2.3.1 Novolin/Actrapid/Insulatard
    5.1.2.3.2 Humulin
    5.1.2.3.3 Insuman
    5.1.2.4 Biosimilar Insulin
    5.1.2.4.1 Insulin Glargine Biosimilars
    5.1.2.4.2 Human Insulin Biosimilars
    5.1.3 Non-insulin Injectable drugs (Value and Volume 2012-2024)
    5.1.3.1 GLP-1 Receptor Agonists
    5.1.3.1.1 Victoza (Liraglutide)
    5.1.3.1.2 Byetta (Exenatide)
    5.1.3.1.3 Bydureon (Exenatide)
    5.1.3.1.4 Trulicity (Dulaglutide)
    5.1.3.1.5 Lyxumia (Lixisenatide)
    5.1.3.2 Amylin Analogue
    5.1.3.2.1 Symlin (Pramlintide)
    5.1.4 Combination Drugs
    5.1.4.1 Combination Insulin
    5.1.4.1.1 NovoMix (Biphasic Insulin Aspart)
    5.1.4.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)
    5.1.4.1.3 Xultophy (Insulin Degludec and Liraglutide)
    5.1.4.2 Oral Combination
    5.1.4.2.1 Janumet (Sitagliptin and Metformin HCl)
    5.2 Geography
    5.2.1 North America
    5.2.1.1 United States (Value and Volume 2012-2024)
    5.2.1.1.1 Oral Anti-diabetic Drugs
    5.2.1.1.2 Insulin
    5.2.1.1.3 Non-Insulin Injectable Drugs
    5.2.1.1.4 Combination Drugs
    5.2.1.1.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.1.2 Canada (Value and Volume 2012-2024)
    5.2.1.2.1 Oral Anti-diabetic Drugs
    5.2.1.2.2 Insulin
    5.2.1.2.3 Non-Insulin Injectable Drugs
    5.2.1.2.4 Combination Drugs
    5.2.1.2.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.1.3 Rest of North America (Value and Volume 2012-2024)
    5.2.1.3.1 Oral Anti-diabetic Drugs
    5.2.1.3.2 Insulin
    5.2.1.3.3 Non-Insulin Injectable Drugs
    5.2.1.3.4 Combination Drugs
    5.2.1.3.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.2 Europe
    5.2.2.1 France (Value and Volume 2012-2024)
    5.2.2.1.1 Oral Anti-diabetic Drugs
    5.2.2.1.2 Insulin
    5.2.2.1.3 Non-Insulin Injectable Drugs
    5.2.2.1.4 Combination Drugs
    5.2.2.1.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.2.2 Germany (Value and Volume 2012-2024)
    5.2.2.2.1 Oral Anti-diabetic Drugs
    5.2.2.2.2 Insulin
    5.2.2.2.3 Non-Insulin Injectable Drugs
    5.2.2.2.4 Combination Drugs
    5.2.2.2.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.2.3 Italy (Value and Volume 2012-2024)
    5.2.2.3.1 Oral Anti-diabetic Drugs
    5.2.2.3.2 Insulin
    5.2.2.3.3 Non-Insulin Injectable Drugs
    5.2.2.3.4 Combination Drugs
    5.2.2.3.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.2.4 Spain (Value and Volume 2012-2024)
    5.2.2.4.1 Oral Anti-diabetic Drugs
    5.2.2.4.2 Insulin
    5.2.2.4.3 Non-Insulin Injectable Drugs
    5.2.2.4.4 Combination Drugs
    5.2.2.4.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.2.5 United Kingdom (Value and Volume 2012-2024)
    5.2.2.5.1 Oral Anti-diabetic Drugs
    5.2.2.5.2 Insulin
    5.2.2.5.3 Non-Insulin Injectable Drugs
    5.2.2.5.4 Combination Drugs
    5.2.2.5.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.2.6 Russia (Value and Volume 2012-2024)
    5.2.2.6.1 Oral Anti-diabetic Drugs
    5.2.2.6.2 Insulin
    5.2.2.6.3 Non-Insulin Injectable Drugs
    5.2.2.6.4 Combination Drugs
    5.2.2.6.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.2.7 Rest of Europe (Value and Volume 2012-2024)
    5.2.2.7.1 Oral Anti-diabetic Drugs
    5.2.2.7.2 Insulin
    5.2.2.7.3 Non-Insulin Injectable Drugs
    5.2.2.7.4 Combination Drugs
    5.2.2.7.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.3 Latin America
    5.2.3.1 Mexico (Value and Volume 2012-2024)
    5.2.3.1.1 Oral Anti-diabetic Drugs
    5.2.3.1.2 Insulin
    5.2.3.1.3 Non-Insulin Injectable Drugs
    5.2.3.1.4 Combination Drugs
    5.2.3.1.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.3.2 Brazil (Value and Volume 2012-2024)
    5.2.3.2.1 Oral Anti-diabetic Drugs
    5.2.3.2.2 Insulin
    5.2.3.2.3 Non-Insulin Injectable Drugs
    5.2.3.2.4 Combination Drugs
    5.2.3.2.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.3.3 Rest of Latin America (Value and Volume 2012-2024)
    5.2.3.3.1 Oral Anti-diabetic Drugs
    5.2.3.3.2 Insulin
    5.2.3.3.3 Non-Insulin Injectable Drugs
    5.2.3.3.4 Combination Drugs
    5.2.3.3.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.4 Asia-Pacific
    5.2.4.1 Japan (Value and Volume 2012-2024)
    5.2.4.1.1 Oral Anti-diabetic Drugs
    5.2.4.1.2 Insulin
    5.2.4.1.3 Non-Insulin Injectable Drugs
    5.2.4.1.4 Combination Drugs
    5.2.4.1.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.4.2 South Korea (Value and Volume 2012-2024)
    5.2.4.2.1 Oral Anti-diabetic Drugs
    5.2.4.2.2 Insulin
    5.2.4.2.3 Non-Insulin Injectable Drugs
    5.2.4.2.4 Combination Drugs
    5.2.4.2.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.4.3 China (Value and Volume 2012-2024)
    5.2.4.3.1 Oral Anti-diabetic Drugs
    5.2.4.3.2 Insulin
    5.2.4.3.3 Non-Insulin Injectable Drugs
    5.2.4.3.4 Combination Drugs
    5.2.4.3.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.4.4 India (Value and Volume 2012-2024)
    5.2.4.4.1 Oral Anti-diabetic Drugs
    5.2.4.4.2 Insulin
    5.2.4.4.3 Non-Insulin Injectable Drugs
    5.2.4.4.4 Combination Drugs
    5.2.4.4.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.4.5 Australia (Value and Volume 2012-2024)
    5.2.4.5.1 Oral Anti-diabetic Drugs
    5.2.4.5.2 Insulin
    5.2.4.5.3 Non-Insulin Injectable Drugs
    5.2.4.5.4 Combination Drugs
    5.2.4.5.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.4.6 Vietnam (Value and Volume 2012-2024)
    5.2.4.6.1 Oral Anti-diabetic Drugs
    5.2.4.6.2 Insulin
    5.2.4.6.3 Non-Insulin Injectable Drugs
    5.2.4.6.4 Combination Drugs
    5.2.4.6.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.4.7 Malaysia (Value and Volume 2012-2024)
    5.2.4.7.1 Oral Anti-diabetic Drugs
    5.2.4.7.2 Insulin
    5.2.4.7.3 Non-Insulin Injectable Drugs
    5.2.4.7.4 Combination Drugs
    5.2.4.7.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.4.8 Indonesia (Value and Volume 2012-2024)
    5.2.4.8.1 Oral Anti-diabetic Drugs
    5.2.4.8.2 Insulin
    5.2.4.8.3 Non-Insulin Injectable Drugs
    5.2.4.8.4 Combination Drugs
    5.2.4.8.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.4.9 Philippines (Value and Volume 2012-2024)
    5.2.4.9.1 Oral Anti-diabetic Drugs
    5.2.4.9.2 Insulin
    5.2.4.9.3 Non-Insulin Injectable Drugs
    5.2.4.9.4 Combination Drugs
    5.2.4.9.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.4.10 Thailand (Value and Volume 2012-2024)
    5.2.4.10.1 Oral Anti-diabetic Drugs
    5.2.4.10.2 Insulin
    5.2.4.10.3 Non-Insulin Injectable Drugs
    5.2.4.10.4 Combination Drugs
    5.2.4.10.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.4.11 Rest of Asia-Pacific (Value and Volume 2012-2024)
    5.2.4.11.1 Oral Anti-diabetic Drugs
    5.2.4.11.2 Insulin
    5.2.4.11.3 Non-Insulin Injectable Drugs
    5.2.4.11.4 Combination Drugs
    5.2.4.11.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.5 Middle East & Africa
    5.2.5.1 Saudi Arabia (Value and Volume 2012-2024)
    5.2.5.1.1 Oral Anti-diabetic Drugs
    5.2.5.1.2 Insulin
    5.2.5.1.3 Non-Insulin Injectable Drugs
    5.2.5.1.4 Combination Drugs
    5.2.5.1.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.5.2 Iran (Value and Volume 2012-2024)
    5.2.5.2.1 Oral Anti-diabetic Drugs
    5.2.5.2.2 Insulin
    5.2.5.2.3 Non-Insulin Injectable Drugs
    5.2.5.2.4 Combination Drugs
    5.2.5.2.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.5.3 Egypt (Value and Volume 2012-2024)
    5.2.5.3.1 Oral Anti-diabetic Drugs
    5.2.5.3.2 Insulin
    5.2.5.3.3 Non-Insulin Injectable Drugs
    5.2.5.3.4 Combination Drugs
    5.2.5.3.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.5.4 Oman (Value and Volume 2012-2024)
    5.2.5.4.1 Oral Anti-diabetic Drugs
    5.2.5.4.2 Insulin
    5.2.5.4.3 Non-Insulin Injectable Drugs
    5.2.5.4.4 Combination Drugs
    5.2.5.4.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.5.5 South Africa (Value and Volume 2012-2024)
    5.2.5.5.1 Oral Anti-diabetic Drugs
    5.2.5.5.2 Insulin
    5.2.5.5.3 Non-Insulin Injectable Drugs
    5.2.5.5.4 Combination Drugs
    5.2.5.5.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.5.6 Rest of Middle & Africa (Value and Volume 2012-2024)
    5.2.5.6.1 Oral Anti-diabetic Drugs
    5.2.5.6.2 Insulin
    5.2.5.6.3 Non-Insulin Injectable Drugs
    5.2.5.6.4 Combination Drugs
    5.2.5.6.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)

    6 MARKET INDICATORS
    6.1 Type 1 Diabetes Population (2012-2024)
    6.2 Type 2 Diabetes Population (2012-2024)

    7 COMPETITIVE LANDSCAPE
    7.1 COMPANY PROFILES
    7.1.1 Novo Nordisk
    7.1.2 Sanofi
    7.1.3 Eli Lilly
    7.1.4 Takeda
    7.1.5 Pfizer
    7.1.6 Janssen Pharmaceuticals
    7.1.7 Astellas
    7.1.8 Boehringer Ingelheim
    7.1.9 Merck and Co.
    7.1.10 AstraZeneca
    7.1.11 Bristol Myers Squibb
    7.1.12 Novartis
    7.2 COMPANY SHARE ANALYSIS
    7.2.1 Novo Nordisk
    7.2.2 Sanofi
    7.2.3 Eli Lilly
    7.2.4 AstraZeneca
    7.2.5 Astellas
    7.2.6 Janssen Pharmaceuticals
    7.2.7 Merck and Co.
    7.2.8 Others

    8 MARKET OPPORTUNITIES AND FUTURE TRENDS

     

    Contact Us:

    Name: Ajay More

    Phone: US +14242530807/ UK +44 20 3239 8187

    Email: [email protected]

    Our Other Reports:

    Global Synthetic Paper Market 2019: Industry Size & Share, Business Strategies, Growth Analysis, Regional Demand, Revenue, Key Manufacturers and 2024 Forecast Research Report

    Powder Coating Equipment Market 2019 Global Manufacturing Size, Share, Opportunities, Future Trends, Top Key Players, Market Share and Global Analysis by Forecast to 2024

    Extraction Fans Market Size 2019: Segmentation with Manufacturers, Regions, Types, Applications, and Forecast by 2024

    Mechanical Keyboard Market Growth 2019 | Global Industry Overview, Business Strategy, Industry Size, Share, and Forecast to 2023